Apic Bio to receive $10M up front & is also eligible to receive ~$45M in milestones upon achievement of regulatory approvals in the US & EU and pre-specified annual net sales along with royalty
uniQure to get global rights for the development & commercialization of APB-102 & adds to its pipeline of gene therapies for neurological disorders. The IND application for APB-102 has been approved by the US FDA & the therapy also received ODD & FTD. The P-I/II study of APB-102 is expected to be initiated in H2’23
In preclinical tests using a SOD1-ALS mouse model, APB-102 significantly increased the survival of the affected mice. At suggested clinical doses, relevant SOD1 reduction in spinal cord motor neurons was also shown in rodents & non-human primates
Ref: Globenewswire | Image: uniQure
Related News:- uniQure Receives EMA’s CHMP Positive Opinion of Etranacogene Dezaparvovec for the Treatment of Adults with Hemophilia B
